Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Trial of IMMH-010 in Patients With Advanced Malignant Solid Tumors

NCT04343859 is registered in ClinicalTrials.gov with Tianjin Chasesun Pharmaceutical Co., LTD as lead sponsor.

NCT NCT04343859
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04343859 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Trial of IMMH-010 in Patients With Advanced Malignant Solid Tumors
Lead sponsor
Tianjin Chasesun Pharmaceutical Co., LTD
Phase
Phase 1
Overall status
Unknown status
Start date
May 14, 2020
Completion date
December 31, 2024
Enrollment
96 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant neoplasms